Memphasys (ASX:MEM) confirmed the RoXsta Mega Cell High-Throughput Assay device was capable of simultaneously processing 96 samples in less than an hour during recent trials, according to a Thursday filing with the Australian bourse.
The diagnostic device has been developed for rapid and high-capacity testing of reactive oxygen species levels in biological fluids, the filing said.
The device has been utilized in various studies, including assessing oxidative stress in cattle and assessing antioxidant levels in professional footballers, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.